Enliven Therapeutics
ELVN
ELVN
113 hedge funds and large institutions have $1.12B invested in Enliven Therapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 25 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.62% more ownership
Funds ownership: 100.95% → 101.57% (+0.62%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
8% less capital invested
Capital invested by funds: $1.22B → $1.12B (-$101M)
Holders
113
Holding in Top 10
8
Calls
$25K
Puts
$7K
Top Buyers
| 1 | +$39.1M | |
| 2 | +$6.54M | |
| 3 | +$5.63M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.49M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$3.06M |
Top Sellers
| 1 | -$7.99M | |
| 2 | -$5.31M | |
| 3 | -$4.78M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.38M |